NBY Earnings
NovaBay Pharmaceuticals Inc
$
0.590
- Overview
- Forecast
- Valuation
- Earnings
Earning Analysis
Welcome to our in-depth analysis of NovaBay Pharmaceuticals Inc(NBY) earnings, offering investors a detailed look into the company’s financial performance, revenue trends, earnings per share (EPS), and market reactions. This page provides a comprehensive overview of NovaBay Pharmaceuticals Inc earnings history, forecasts, and key financial metrics, empowering you with the data needed to make informed investment decisions. Whether you're tracking quarterly results, analyzing earnings surprises, or exploring future projections, our detailed breakdown covers it all.
Earnings Forecast
Revenue
EPS
Currency: USD
Actual
Estimate
Surprise Analysis
| FY2024Q3 | 2024-11-07 | - | -0.28 | -0.60 | -114.29 | 2.63M | 2.44M | -7.01 | -2.78 | -1.39 |
| FY2024Q2 | 2024-08-13 | After Hours | -1.23 | -1.37 | +11.38 | 3.16M | 2.40M | -23.93 | -4.17 | +16.67 |
| FY2024Q1 | 2024-05-09 | - | - | -0.14 | - | 3.28M | 2.63M | -19.79 | - | +11.11 |
| FY2023Q4 | 2024-03-26 | - | - | -0.95 | - | 3.40M | 3.73M | +9.62 | +7.69 | -23.08 |
NBY Earnings Analysis
Our earnings analysis provides a granular look at the company’s performance across recent fiscal quarters, highlighting key metrics such as revenue, EPS, and operating margins. By examining actual results against analyst estimates, we uncover trends and surprises that drive stock price movements, offering valuable insights for both short-term traders and long-term investors.
In the most recent quarter, NovaBay Pharmaceuticals Inc reported performance for FY2024Q3, announced on 2024-11-07. The company achieved an EPS of -0.60, compared to analyst estimates of -0.28 by -114.29% . Revenue for the quarter reached 2.44M compared to expectations of 2.63M by -7.01% .
The stock price reacted with a -2.78% one-day change and a -1.39% five-day change following the earnings release. These movements reflect market reaction in NovaBay Pharmaceuticals Inc growth trajectory and strategic initiatives.
NBY Earnings Forecast
Looking ahead, NovaBay Pharmaceuticals Inc(NBY) remains a focal point for investors seeking growth opportunities. Analyst forecasts for 2025/Q1 project quarter revenue of 3.00M and an EPS of -0.24.
However, recent estimate revisions provide additional context. Over the past three months, revenue estimates for FY2025 have been No Change by 0%, while EPS estimates have been No Change by 0%. For the upcoming Q2 2025, revenue estimates have been adjusted No Change by 0% . These revisions correlate with a 0.43% change in stock price over the same period, suggesting potential buying opportunities for investors who believe in NovaBay Pharmaceuticals Inc long-term fundamentals.
The relationship between earnings forecast revisions and stock price movements is critical for investors. Positive revisions in revenue or EPS often signal strengthening fundamentals, making temporary price dips attractive entry points. Conversely, downward revisions may reflect short-term challenges.
Estimate Revision
The chart shows the correlation between NBY's stock price and earnings forecast revisions. Positive revisions in Revenue or EPS often strengthen the stock's fundamentals, making price dips potential buying opportunities.
Revenue Estimates for FY2025
No Change
0.00%
In Past 3 Month
EPS Estimates for FY2025
No Change
0.00%
In Past 3 Month
Revenue Estimates for Q2 2025
No Change
0.00%
In Past 3 Month
Stock Price
Go Up
+0.43%
In Past 3 Month
1Y
3Y
5Y
Annual FY 2025
Currency: USD
1Y
3Y
5Y
--
Revenue Estimate-Annual FY 2025:12.00M
--
EPS Estimate-Annual FY 2025:-0.86
—
Stock Price0.59
NBY Revenue and EPS Performance: A Historical Perspective
NovaBay Pharmaceuticals Inc revenue and earnings per share (EPS) performance over recent quarters provides a clear picture of its financial health. Below is a detailed breakdown of the company’s earnings history, showcasing actual results, analyst estimates, and surprise percentages for key fiscal quarters:
FY2024Q3 (2024-11-07,):
EPS: -0.60 (Actual) vs.-0.28 (Estimate) (-114.29%)
Revenue: 2.44M (Actual) vs. 2.63M (Estimate) (-7.01%)
Price Reaction: -2.78%(1-Day), -1.39%(5-Day)
FY2024Q2 (2024-08-13,After Hours):
EPS: -1.37 (Actual) vs.-1.23 (Estimate) (11.38%)
Revenue: 2.40M (Actual) vs. 3.16M (Estimate) (-23.93%)
Price Reaction: -4.17%(1-Day), 16.67%(5-Day)
FY2024Q1 (2024-05-09,):
EPS: -0.14 (Actual) vs. (Estimate) (%)
Revenue: 2.63M (Actual) vs. 3.28M (Estimate) (-19.79%)
Price Reaction: 0.00%(1-Day), 11.11%(5-Day)
Earnings Reaction
The chart below shows how NBY performed 10 days before and after its earnings report, based on data from the past quarters. Typically, NBY sees a +0.25% change in stock price 10 days leading up to the earnings, and a +7.81% change 10 days following the report. On the earnings day itself, the stock moves by +5.32%. This data can give you a slight idea of what to expect for the next quarter's release.
For example, in SEP/2024, the stock changed -0.69% on the day following the earnings release and then changed by 2.98% over the next 10 days. These patterns provide investors with valuable insights into potential price movements and help inform trading strategies around earnings events.
Transcript Summary
No Data
People Also Watch
TTNP
Titan Pharmaceuticals Inc
4.930
USD
+2.28%
RETO
ReTo Eco-Solutions Inc
2.120
USD
-0.93%
NIVF
NewGenIvf Group Ltd
1.900
USD
-3.06%
NCPL
Netcapital Inc
2.070
USD
-20.99%
ZVSA
Zyversa Therapeutics Inc
0.277
USD
-76.45%
SNOA
Sonoma Pharmaceuticals Inc
3.052
USD
+1.73%
ASTI
Ascent Solar Technologies Inc
2.210
USD
0.00%
OST
Ostin Technology Group Co Ltd
2.050
USD
+13.26%
FAQ
What were the key highlights of NBY’s latest earnings report for FY2024Q3?
NBY reported its FY2024Q3 earnings on 2024-11-07, showcasing a revenue of 2.44M against an estimate of 2.63M, resulting in a -7.01% surprise. The EPS was -0.6, surpassing the expected -0.28 by -114.29% . The stock experienced a -2.78% price change on the earnings day and a -1.39% change over the next five days, reflecting market reactions to the results.
How did NBY’s stock price react after the FY2024Q3 earnings release?
What are the revenue and EPS estimates for NBY for 2025/Q1?
How does NBY’s stock price correlate with earnings forecast revisions?
What should investors expect from NBY’s next earnings report?